Description     Claims     Drawing  

Ann Intern Med   [0004] 
Clin Microbiol Infect   [0004] 
Nat Rev Microbiol   [0007] 
Lancet   [0008] 
Lancet Infect Dis   [0009] 
N Engl J Med   [0009]  [0009] 
Lancet Infect Dis   [0009] 
Clostridium difficile infection diagnosis   [0048] 
J Clin Microbiol.   [0061] 
J Bacteriol.   [0062] 
Treatment of Clostridium difficile infections: old and new approaches   [0090] 
Anaerobe   [0092] 
Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage   [0163] 
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis   [0163] 
Colonisation and transmission of Clostridium difficile in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis   [0163] 
Clostridium difficile infection: new developments in epidemiology and pathogenesis   [0163] 
Clostridium difficile-associated Enteric Disease   [0163] 
Can we identify patients at high risk of recurrent Clostridium difficile infection?   [0163] 
New trends in Clostridium difficile virulence and pathogenesis   [0163] 
The host immune response to Clostridium difficile   [0163] 
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea   [0163] 
Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile   [0163] 
Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease   [0163] 
Molecular characterization of fliD gene encoding flagellar cap and its expression among Clostridium difficile isolates from different serogroups   [0163] 
Characterization of a cell surface protein of Clostridium difficile with adhesive properties   [0163] 
Interference in immunoassay   [0163] 
Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains   [0163] 
Toxin B is essential for virulence of Clostridium difficile   [0163] 
Serum antibody response to toxins A and B of Clostridium difficile   [0163] 
Passive acquisition of protective antibodies reactive with Bordetella pertussis in newborns via placental transfer and breast-feeding   [0163] 
Incidence and origin of Clostridium difficile in neonates   [0163] 
Clostridium difficile colitis   [0163] 
Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee   [0163] 
Treatment of Clostridium difficile infection   [0163] 
Recurrent Clostridium difficile disease: epidemiology and clinical characteristics   [0163] 
Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial   [0163] 
Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991   [0163] 
Risk factors for early recurrent Clostridium difficile-associated diarrhea   [0163] 
Clostridium difficile colitis: factors influencing treatment failure and relapse--a prospective evaluation   [0163] 
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)   [0163]